<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Summers, Jaye</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Freedman, Mark</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">REFLEXION Trial</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-05-20 11:31:42</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-15</style></pages><abstract><style  face="normal" font="default" size="100%">Many who experience a first demyelinating clinical event will convert to clinically definite multiple sclerosis. Data from the REFLEX and REFLEXION trials suggest that patients who receive early treatment with interferon beta 1-a will convert to multiple sclerosis later than patients who took placebo prior to receiving interferon beta 1-a.</style></abstract><number><style face="normal" font="default" size="100%">9</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>